In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Europe’s Big Pharma Players Begin Tricky 2022 In Style

Big pharma players have embraced a tricky operating environment in 2022 so far, treading a tightrope with political and financial challenges impacting their decision making and threatening to blow them off balance. However, what is not in doubt is the healthy growth experienced by those companies based around mainland Europe and the UK.

Europe Growth Market Intelligence

China Takes A Bigger Role In The World Pharma Stage

2021 saw a record number of novel drug launches and the size of the pipeline topped 20,000 candidates for the first time, new analysis shows, while China came of age as a pharma player.

Companies China Launches

Putting The Patient First: The Challenge And Opportunities To Improve Rare-Disease Therapy Development


Advances in identifying the genetic causes of diseases, and particularly cancers, coupled with regulatory incentives to encourage the development of therapeutic approaches to once poorly managed orphan diseases have fueled a surge in exciting new medicines. To address some of these issues and explore potential solutions, Simbec-Orion in collaboration with Informa Pharma Intelligence convened a round table of experts attending the BIO International Convention

Read More

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

COVID-19 Gives US Biopharma Plenty Of Q1 Cover

Pfizer, Merck, Eli Lilly and Gilead all benefited from the sale of vaccines and treatments for COVID-19, but the long-term growth prospects remain uncertain, and more so for some than others.

North America Market Intelligence

Providing A Better Last Mile Experience For Medtech And Patients

Every part of health care today needs connectivity, says Cisco’s Troy Yoder. He explaines the unique role the company’s technology plays in ensuring patients get the best care the medtech industry can offer.

Digital Health Medical Device

2021 Global Biopharma R&D Productivity And Growth Ranking

A turbulent 2021: we are now in our eighth year of reviewing R&D productivity and corporate growth of the top 30 biopharma companies. While 2021 was dominated by the COVID-19 pandemic, biopharma as a whole had a good but not great year.

Growth Research & Development

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

Microbot Medical Hopes To Bring First Disposable Endovascular Robot To US Market

Microbot Medical CEO Harel Gadot said a recent regulatory filing marks an important milestone in his company' efforts to bring the world’s first fully disposable endovascular robot to market.

Innovation Medical Device

Seven Trending Technologies On The Cusp Of Mainstream Uptake

At HIMSS22, NEO.Life’s Jane Metcalfe identified seven trending technologies that are set to move from the fringes of medicine to the center of attention.

Innovation Medical Device

Don’t Trust That (Femtech) App – Most Health Apps Don’t Meet ORCHA’s Standards

Of thousands of health apps, including femtech apps, reviewed by ORCHA, only 20% meet the required standards to be considered “trustworthy.”

Artificial Intelligence Digital Health
Data Spotlight

Infographic: 2021 Top Big Pharma Deal-Makers

Roche/Genentech was the busiest deal-maker in big pharma for second consecutive year in 2021, followed by Sanofi, Takeda, Lilly, Novartis and Pfizer.

2021 Deal-Making Snapshot

M&A deals valued at $10bn or more were scarce in 2021, as the industry focused on easier-to-integrate bolt-ons. Alliance activity increased, but the average value on licensing and partnership deals was lower than in 2020.

Alzheimer’s Disease: Many Failures Before One Success

For Biogen/Eisai’s success with Aduhelm, there were 93 failures in the anti-amyloid field. In Vivo's sister publication Scrip took a look back at how the pipeline for amyloid-targeting Alzheimer’s drugs progressed over the past decade to showcase exactly how difficult the Alzheimer’s space has been.

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

From Regulatory Affairs To R&D, Sanofi’s Mura Has Broad Strategic View

From a legal family in her native Brazil, Raquel Mura built on her passion for science to work in consumer health care, nutritionals and pharmaceuticals, rising to an R&D leadership position at Sanofi.

Rising Leaders Commercial

Elizabeth Jungman: Interpreter Of The FDA’s Policy Crystal Ball

The Center for Drug Evaluation and Research’s policy guru must think about the future, along with the present, in her position as director of the Office of Regulatory Policy.

Leadership Policy

Muvon Therapeutics: The Road To Expansion

Deana Mohr, Muvon Therapeutics’ co-founder and chief executive, and one of In Vivo’s 2022 Rising Leaders, aspires to push the organization to the next level by scaling up the company and developing its therapies into marketable products.

Leadership Regenerative Medicine

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

Generics Industry Braces For New Wave Of Price Pressure

With pricing pressures already creeping up in recent years, 2022 is set to see the generics industry caught in the middle as prices are further squeezed while costs continue to rise. As major players prepare to announce their first-quarter financial results, In Vivo looks at views from industry leaders on how these pressures are affecting their businesses, and how they can be expected to play out.

Europe US States

Compassionate Use Programs In APAC: China Breaks The Ice

Compassionate use programs (CUP) are a developing field in Asian countries. In the majority of Asian states, the CU applies to Named-Patients Program (NPP). In the most countries, understanding of CUP for unapproved drugs is poor among the public, and even for professional communities. 

Market Access Asia Pacific

Transforming Patient Engagement At Novartis

Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action. 

Rising Leaders Business Strategies

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

How Can Pharma Seek To Discuss Gender Diversity?

As gender-neutral language becomes more widely used throughout the business community, the pharmaceutical industry must confront how it approaches the matter of gendered language in healthcare communications.

Diversity & Inclusion Market Intelligence

COVID-19 Gives US Biopharma Plenty Of Q1 Cover

Pfizer, Merck, Eli Lilly and Gilead all benefited from the sale of vaccines and treatments for COVID-19, but the long-term growth prospects remain uncertain, and more so for some than others.

North America Market Intelligence

Deals In Depth: April 2022

In the top April alliance by deal value, Jazz Pharmaceuticals acquired exclusive global development and commercialization rights to Werewolf Therapeutics' WTX-613. Preclinical WTX-613 is an engineered IFN2b cytokine pro-drug that is activated specifically within the tumor microenvironment where it can stimulate IFNα receptors on cancer-fighting immune effector cells. Jazz expects to submit an IND application to the FDA for WTX-613 in 2023. Jazz paid $15M up front and Werewolf is eligible to receive development, regulatory and commercial milestone payments of up to $1.26bn, plus royalties.

Deals Financing
UsernamePublicRestriction

Register